Affordable Access

deepdyve-link
Publisher Website

Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes.

Authors
  • Abdelsaid, Mohammed1
  • Ma, Handong1
  • Coucha, Maha2
  • Ergul, Adviye3
  • 1 Charlie Norwood Veterans Administration Medical Center, University of Georgia College of Pharmacy, USA; Department of Physiology, Georgia Regents University, Augusta, GA, USA. , (Georgia)
  • 2 Department of Physiology, Georgia Regents University, Augusta, GA, USA. , (Georgia)
  • 3 Charlie Norwood Veterans Administration Medical Center, University of Georgia College of Pharmacy, USA; Center for Pharmacy and Experimental Therapeutics, University of Georgia College of Pharmacy, USA; Department of Physiology, Georgia Regents University, Augusta, GA, USA. Electronic address: [email protected] , (Georgia)
Type
Published Article
Journal
Life sciences
Publication Date
Nov 24, 2014
Volume
118
Issue
2
Pages
263–267
Identifiers
DOI: 10.1016/j.lfs.2013.12.231
PMID: 24434796
Source
Medline
Keywords
License
Unknown

Abstract

These results suggest that contractile response is not affected by glycemic control or ET-receptor antagonism. Meanwhile, dual ET-receptor blockade is effective in partially improving endothelium-dependent relaxation and myogenic response in a blood pressure-independent manner even after established cerebrovascular dysfunction and offers therapeutic potential.

Report this publication

Statistics

Seen <100 times